109 results
Page 2 of 6
8-K
72zdpal9b88z
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
424B5
qsd9o5hec735i5r3
24 Mar 22
Prospectus supplement for primary offering
4:15pm
424B5
i9h736o7n58ezqm1bkyn
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-10.1
ztdtvw4vq 9co8pymff
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
424B3
3kmkmuktezts ij
12 Apr 21
Prospectus supplement
1:44pm
S-3
wvctca2 8zs
2 Apr 21
Shelf registration
12:00am
D
sgezmu8w0ix ijwp3zh
19 Feb 21
$10.24M in equity / options, sold $10.24M, 18 investors
9:26am
8-K
EX-10.1
1x6677znja4
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.2
t8zhw
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.1
eaweijo4ziw8th8s8i3o
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
424B4
ncgoreh
5 Oct 20
Prospectus supplement with pricing info
4:16pm